Juying Wei

789 total citations
44 papers, 380 citations indexed

About

Juying Wei is a scholar working on Oncology, Hematology and Pathology and Forensic Medicine. According to data from OpenAlex, Juying Wei has authored 44 papers receiving a total of 380 indexed citations (citations by other indexed papers that have themselves been cited), including 19 papers in Oncology, 19 papers in Hematology and 11 papers in Pathology and Forensic Medicine. Recurrent topics in Juying Wei's work include Acute Myeloid Leukemia Research (14 papers), Lymphoma Diagnosis and Treatment (10 papers) and Multiple Myeloma Research and Treatments (6 papers). Juying Wei is often cited by papers focused on Acute Myeloid Leukemia Research (14 papers), Lymphoma Diagnosis and Treatment (10 papers) and Multiple Myeloma Research and Treatments (6 papers). Juying Wei collaborates with scholars based in China, United States and Poland. Juying Wei's co-authors include Wenbin Qian, Jie Jin, Liangshun You, Chunmei Yang, Chaoting Zhang, Zheming Lu, Shenhe Jin, Xiaojun Guo, Wen Lei and Ken H. Young and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Scientific Reports.

In The Last Decade

Juying Wei

38 papers receiving 375 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Juying Wei China 12 212 105 81 76 75 44 380
Victor A. Chow United States 8 214 1.0× 80 0.8× 50 0.6× 77 1.0× 77 1.0× 29 359
Miki Ando Japan 12 233 1.1× 152 1.4× 151 1.9× 34 0.4× 130 1.7× 65 453
Sebastian Klobuch Germany 14 224 1.1× 137 1.3× 194 2.4× 68 0.9× 22 0.3× 36 463
Len Farol United States 8 158 0.7× 93 0.9× 60 0.7× 106 1.4× 165 2.2× 12 389
J Palou Spain 13 133 0.6× 117 1.1× 61 0.8× 132 1.7× 84 1.1× 32 456
Michaël Loschi France 12 166 0.8× 217 2.1× 335 4.1× 37 0.5× 34 0.5× 37 626
Arianna Brevi Italy 9 142 0.7× 215 2.0× 143 1.8× 32 0.4× 32 0.4× 11 405
Martina Magni Italy 10 136 0.6× 144 1.4× 64 0.8× 25 0.3× 42 0.6× 19 324
Pierre Sesques France 10 259 1.2× 60 0.6× 55 0.7× 13 0.2× 154 2.1× 27 359

Countries citing papers authored by Juying Wei

Since Specialization
Citations

This map shows the geographic impact of Juying Wei's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Juying Wei with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Juying Wei more than expected).

Fields of papers citing papers by Juying Wei

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Juying Wei. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Juying Wei. The network helps show where Juying Wei may publish in the future.

Co-authorship network of co-authors of Juying Wei

This figure shows the co-authorship network connecting the top 25 collaborators of Juying Wei. A scholar is included among the top collaborators of Juying Wei based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Juying Wei. Juying Wei is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Zhou, De, Xianbo Huang, Lixia Zhu, et al.. (2025). Ruxolitinib combined with dexamethasone for adult patients with newly diagnosed hemophagocytic lymphohistiocytosis in China. Blood. 146(3). 318–327. 2 indexed citations
3.
Yin, Xuejiao, Yi Liu, Jianping Ge, et al.. (2025). IFN-γ promotes the progression of iMCD by activating inflammatory monocytes. Blood. 146(1). 76–88.
4.
You, Liangshun, Yi Liu, Wenyuan Mai, et al.. (2024). Venetoclax plus cytarabine and azacitidine in relapsed/refractory AML: An open-label, single-arm, phase 2 study. European Journal of Cancer. 202. 113979–113979. 3 indexed citations
5.
6.
Zhang, Xiang, Ziwei Wang, Lixia Liu, et al.. (2023). New insights into the clinical characteristics of SETD2‐mutated acute myeloid leukaemia. British Journal of Haematology. 202(1). 111–115. 2 indexed citations
7.
Pan, Jiajia, Yile Zhou, Liping Mao, et al.. (2023). Gilteritinib‐based combination therapy in adult relapsed/refractory FLT3 ‐mutated acute myeloid leukaemia. British Journal of Haematology. 204(3). 861–870. 1 indexed citations
8.
Shen, Huafei, Yuanfei Shi, Yanchun Zhao, et al.. (2023). Dyslipidemia in diffuse large B-cell lymphoma based on the genetic subtypes: a single-center study of 259 Chinese patients. Frontiers in Oncology. 13. 1172623–1172623. 3 indexed citations
9.
Wei, Juying, et al.. (2023). A hybrid energy-based and AI-based screening approach for the discovery of novel inhibitors of JAK3. Frontiers in Medicine. 10. 1182227–1182227. 2 indexed citations
10.
Wang, Li, Jianda Hu, Wenbin Qian, et al.. (2021). Outcomes in refractory diffuse large B‐cell lymphoma: results from a multicenter real‐world study in China. Cancer Communications. 41(3). 229–239. 17 indexed citations
11.
Lei, Wen, Chaoting Zhang, Chunmei Yang, et al.. (2020). CD19-specific CAR T Cells that Express a PD-1/CD28 Chimeric Switch-Receptor are Effective in Patients with PD-L1–positive B-Cell Lymphoma. Clinical Cancer Research. 27(2). 473–484. 104 indexed citations
12.
Zhang, Piaopiao, Jie Wang, Sheng Zhang, et al.. (2020). <p>Clinical Characteristics and Risk Factors for Bloodstream Infection Due to Carbapenem-Resistant <em>Klebsiella pneumoniae</em> in Patients with Hematologic Malignancies</p>. Infection and Drug Resistance. Volume 13. 3233–3242. 20 indexed citations
13.
Yang, Chunmei, et al.. (2020). <p>Sustained Remission of Relapsed or Refractory Mantle Cell Lymphoma After 4-1BB-Based CD19-Directed CAR-T Therapy</p>. OncoTargets and Therapy. Volume 13. 12163–12168. 3 indexed citations
14.
Tang, Huifen, Hui Zhou, Juying Wei, et al.. (2019). Clinicopathologic significance and therapeutic implication of de novo CD5+ diffuse large B-cell lymphoma. Hematology. 24(1). 446–454. 11 indexed citations
15.
You, Liangshun, Liping Mao, Juying Wei, et al.. (2017). The crosstalk between autophagic and endo-/exosomal pathways in antigen processing for MHC presentation in anticancer T cell immune responses. Journal of Hematology & Oncology. 10(1). 165–165. 35 indexed citations
16.
Zhou, Xinping, Juying Wei, Yinjun Lou, et al.. (2017). Salvage therapy with lenalidomide containing regimen for relapsed/refractory Castleman disease: a report of three cases. Frontiers of Medicine. 11(2). 287–292. 7 indexed citations
17.
Hu, Chao, Mengxia Yu, Yanling Ren, et al.. (2017). PP2A inhibition from LB100 therapy enhances daunorubicin cytotoxicity in secondary acute myeloid leukemia via miR-181b-1 upregulation. Scientific Reports. 7(1). 2894–2894. 18 indexed citations
18.
19.
Wang, Wei, Zhimei Chen, Mengxia Yu, et al.. (2015). [Clinical and cytogenetic study of chromosome 1 abnormality in myelodysplastic syndrome].. PubMed. 36(10). 818–23. 1 indexed citations
20.
Wei, Juying, Feifei Chen, Wenyuan Mai, et al.. (2010). Novel influenza A (H1N1) in patients with hematologic disease. Leukemia & lymphoma. 51(11). 2079–2083. 10 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Victor A. Chow Breakdown of academic impact, for papers by Miki Ando Breakdown of academic impact, for papers by Sebastian Klobuch Breakdown of academic impact, for papers by Len Farol Breakdown of academic impact, for papers by J Palou Breakdown of academic impact, for papers by Michaël Loschi Breakdown of academic impact, for papers by Arianna Brevi Breakdown of academic impact, for papers by Martina Magni Breakdown of academic impact, for papers by Pierre Sesques
Rankless by CCL
2026